Biomea Fusion is a biopharmaceutical company that concentrates on finding and creating covalent small molecule drugs for metabolic diseases and genetically defined cancers. Their primary product, BMF-219, is a covalent inhibitor of menin which is a transcriptional regulator in multiple cancers. Headquartered in Redwood City, California, the company was created in 2017.